Singh Shawn 4
4 · VistaGen Therapeutics, Inc. · Filed May 16, 2022
Insider Transaction Report
Form 4
Singh Shawn
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Exercise/Conversion
Common Stock
2022-05-12$1.00/sh+100,000$100,000→ 148,998 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-05-12−100,000→ 70,000 totalExercise: $1.00Exp: 2029-09-05→ Common Stock (100,000 underlying)
Holdings
- 26,234(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Stock option vested 25% on the grant date of September 5, 2019, with the remainder vesting monthly over the 36 months thereafter.